PCM
VKTX icon

Prelude Capital Management’s Viking Therapeutics VKTX Stock Holding History

Prelude Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,000
Closed -$820K – 1516
2024
Q1 		$820K Buy
+10,000
New +$445K 0.04% 451
2020
Q3 		– Sell
-200
Closed -$1K – 2391
2020
Q2 		$1K Buy
+200
New +$1.33K ﹤0.01% 1892

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Prelude Capital Management's VKTX Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Viking Therapeutics (VKTX) in Q1 2026: 15,051 shares worth $490K. The stake represents 0.04% of the portfolio and ranks #525 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in VKTX as recently as Q1 2025.

Prelude Capital Management first reported a position in VKTX in Q2 2018 and has held it in 8 quarters since. The position peaked at $2.16M in Q4 2024. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Prelude Capital Management held 15,051 shares of Viking Therapeutics worth $490K as of Q1 2026.
  • Viking Therapeutics was a new Prelude Capital Management position in Q1 2026.
  • Viking Therapeutics made up 0.04% of Prelude Capital Management's portfolio in Q1 2026, its #525 holding.
  • Prelude Capital Management first reported a position in Viking Therapeutics in Q2 2018 and has held it in 8 quarters since.
  • Prelude Capital Management's Viking Therapeutics position peaked at $2.16M in Q4 2024.
  • 412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.